Myriad Genetics (MYGN) and Personalis (PSNL) announced a non-exclusive collaboration through which Myriad will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners who use the MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoice CDx cancer tests. Financial details of the partnership were not disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
- Myriad Genetics 6.47M share Spot Secondary priced at $17.00
- Myriad Genetics to Participate in Stephens Annual Investment Conference
- Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
- Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
